Advertisement

Immunogenetics

, Volume 71, Issue 5–6, pp 433–436 | Cite as

Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab

  • Peter A. JohanssonEmail author
  • Andrew Stark
  • Jane M. Palmer
  • Kieron Bigby
  • Kelly Brooks
  • Olivia Rolfe
  • Antonia L. Pritchard
  • Kevin Whitehead
  • Sunil Warrier
  • William Glasson
  • Nicholas K. Hayward
Short Communication

Abstract

There is currently no effective treatment for metastasised uveal melanoma (UM). Recently, it was reported that a UM patient was responsive to checkpoint inhibitor (CI) treatment, due to a high tumour mutation burden correlated with a germline loss-of-function MBD4 mutation. Here, we report on another UM patient who carried an MBD4 germline nonsense variant (p.Leu563Ter) and her tumour showed a fivefold higher than average mutation burden. We confirmed the association between germline loss-of-function variant in MBD4 and CI response. The patient experienced stable disease (10 months) and survived 2 years with metastatic disease, which is twice as long as median survival. Additionally, the frequency of MBD4 loss-of-function variants in reported UM cohorts was > 20 times higher than in an aggregated population genome database (P < 5 × 10−5), implying a potential role as UM predisposition gene. These findings provide a strong basis for the inclusion of MBD4 in the screening of potential UM-prone families as well as stratification of immunotherapy.

Keywords

MBD4 Uveal melanoma Mutation Immunotherapy Predisposition gene 

Notes

Acknowledgments

We are indebted to the patient and her family and acknowledge the contribution of Dr. Grant Cameron, along with the many clinicians and allied health professionals involved in her care. We are grateful to Dr. Robert Rawson, Dr. Michael Walsh, Dr. Ken Dutton-Regester, Dr. Lauren Aoude, Madeleine Howlie and Hayley Hamilton for input into this study.

Funding information

The work was funded by the National Health and Medical Research Council of Australia (NHMRC 1093017). N.K.H. is supported by a fellowship from the NHMRC (1117663).

Compliance with ethical standards

Ethics approval was obtained from the Human Research Ethics Committees of the QIMR Berghofer Medical Research Institute. Written informed consent was obtained from the patient.

Supplementary material

251_2019_1108_MOESM1_ESM.pdf (792 kb)
Figure S1 (PDF 791 kb)
251_2019_1108_MOESM2_ESM.pdf (527 kb)
Figure S2 (PDF 527 kb)

References

  1. Alexandrov LB et al (2013) Signatures of mutational processes in human cancer. Nature 500:415–421.  https://doi.org/10.1038/nature12477 CrossRefGoogle Scholar
  2. Damato B, Heimann H (2013) Personalized treatment of uveal melanoma. Eye (Lond) 27:172–179.  https://doi.org/10.1038/eye.2012.242 CrossRefGoogle Scholar
  3. Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 3:1122–1129.  https://doi.org/10.1158/2159-8290.CD-13-0330 CrossRefGoogle Scholar
  4. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45:133–135.  https://doi.org/10.1038/ng.2523 CrossRefGoogle Scholar
  5. Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A (1999) The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature 401:301–304.  https://doi.org/10.1038/45843 CrossRefGoogle Scholar
  6. Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J, Gerdes AM, Jönsson G, Hayward NK (2016) Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7:4624–4631.  https://doi.org/10.18632/oncotarget.6614 Google Scholar
  7. Lek M et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291.  https://doi.org/10.1038/nature19057 CrossRefGoogle Scholar
  8. Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, Lohmann DR, Zeschnigk M (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45:933–936.  https://doi.org/10.1038/ng.2674 CrossRefGoogle Scholar
  9. Oliva M, Rullan AJ, Piulats JM (2016) Uveal melanoma as a target for immune-therapy. Ann Transl Med 4:172.  https://doi.org/10.21037/atm.2016.05.04 CrossRefGoogle Scholar
  10. Polkowska M, Czepielewska E, Kozlowska-Wojciechowska M (2016) Drug combinations as the new standard for melanoma treatment. Curr Treat Options in Oncol 17:61.  https://doi.org/10.1007/s11864-016-0436-y CrossRefGoogle Scholar
  11. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, Ibrahim F, Bruggeman C, Gasmi B, Zappasodi R, Maeda Y, Sander C, Garon EB, Merghoub T, Wolchok JD, Schumacher TN, Chan TA (2015) Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348:124–128.  https://doi.org/10.1126/science.aaa1348 CrossRefGoogle Scholar
  12. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfield L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, Woodman SE, Abdel-Rahman MH, Akbani R, Ally A, Auman JT, Babur O, Balasundaram M, Balu S, Benz C, Beroukhim R, Birol I, Bodenheimer T, Bowen J, Bowlby R, Bristow CA, Brooks D, Carlsen R, Cebulla CM, Chang MT, Cherniack AD, Chin L, Cho J, Chuah E, Chudamani S, Cibulskis C, Cibulskis K, Cope L, Coupland SE, Danilova L, Defreitas T, Demchok JA, Desjardins L, Dhalla N, Esmaeli B, Felau I, Ferguson ML, Frazer S, Gabriel SB, Gastier-Foster JM, Gehlenborg N, Gerken M, Gershenwald JE, Getz G, Gibb EA, Griewank KG, Grimm EA, Hayes DN, Hegde AM, Heiman DI, Helsel C, Hess JM, Hoadley KA, Hobensack S, Holt RA, Hoyle AP, Hu X, Hutter CM, Jager MJ, Jefferys SR, Jones CD, Jones SJM, Kandoth C, Kasaian K, Kim J, Kimes PK, Kucherlapati M, Kucherlapati R, Lander E, Lawrence MS, Lazar AJ, Lee S, Leraas KM, Lichtenberg TM, Lin P, Liu J, Liu W, Lolla L, Lu Y, Iype L, Ma Y, Mahadeshwar HS, Mariani O, Marra MA, Mayo M, Meier S, Meng S, Meyerson M, Mieczkowski PA, Mills GB, Moore RA, Mose LE, Mungall AJ, Mungall KL, Murray BA, Naresh R, Noble MS, Oba J, Pantazi A, Parfenov M, Park PJ, Parker JS, Penson A, Perou CM, Pihl T, Pilarski R, Protopopov A, Radenbaugh A, Rai K, Ramirez NC, Ren X, Reynolds SM, Roach J, Robertson AG, Roman-Roman S, Roszik J, Sadeghi S, Saksena G, Sastre X, Schadendorf D, Schein JE, Schoenfield L, Schumacher SE, Seidman J, Seth S, Sethi G, Sheth M, Shi Y, Shields C, Shih J, Shmulevich I, Simons JV, Singh AD, Sipahimalani P, Skelly T, Sofia H, Soloway MG, Song X, Stern MH, Stuart J, Sun Q, Sun H, Tam A, Tan D, Tang M, Tang J, Tarnuzzer R, Taylor BS, Thiessen N, Thorsson V, Tse K, Uzunangelov V, Veluvolu U, Verhaak RGW, Voet D, Walter V, Wan Y, Wang Z, Weinstein JN, Wilkerson MD, Williams MD, Wise L, Woodman SE, Wong T, Wu Y, Yang L, Yang L, Yau C, Zenklusen JC, Zhang J, Zhang H, Zmuda E (2017) Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32:204–220 e215.  https://doi.org/10.1016/j.ccell.2017.07.003 CrossRefGoogle Scholar
  13. Rodrigues M, Mobuchon L, Houy A, Fiévet A, Gardrat S, Barnhill RL, Popova T, Servois V, Rampanou A, Mouton A, Dayot S, Raynal V, Galut M, Putterman M, Tick S, Cassoux N, Roman-Roman S, Bidard FC, Lantz O, Mariani P, Piperno-Neumann S, Stern MH (2018) Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun 9:1866.  https://doi.org/10.1038/s41467-018-04322-5 CrossRefGoogle Scholar
  14. Sanders MA et al (2018) MBD4 guards against methylation damage and germline deficiency predisposes to clonal hematopoiesis and early-onset AML. Blood.  https://doi.org/10.1182/blood-2018-05-852566
  15. Virgili G et al (2008) Survival in patients with uveal melanoma in Europe. Arch Ophthalmol 126:1413–1418.  https://doi.org/10.1001/archopht.126.10.1413 CrossRefGoogle Scholar
  16. Waszak SM et al (2017) Germline determinants of the somatic mutation landscape in 2,642 cancer genomes. bioRxiv.  https://doi.org/10.1101/208330
  17. Yang J, Manson DK, Marr BP, Carvajal RD (2018) Treatment of uveal melanoma: where are we now? Ther Adv Med Oncol 10:1758834018757175.  https://doi.org/10.1177/1758834018757175 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Peter A. Johansson
    • 1
    Email author
  • Andrew Stark
    • 2
  • Jane M. Palmer
    • 1
  • Kieron Bigby
    • 3
    • 4
    • 5
  • Kelly Brooks
    • 1
  • Olivia Rolfe
    • 2
  • Antonia L. Pritchard
    • 1
    • 6
  • Kevin Whitehead
    • 7
  • Sunil Warrier
    • 2
  • William Glasson
    • 2
  • Nicholas K. Hayward
    • 1
  1. 1.QIMR Berghofer Medical Research InstituteBrisbaneAustralia
  2. 2.Queensland Ocular Oncology ServiceThe Terrace Eye CentreBrisbaneAustralia
  3. 3.Montserrat Cancer CareNorth Lakes Day HospitalNorth LakesAustralia
  4. 4.Redcliffe HospitalRedcliffeAustralia
  5. 5.School of MedicineUniversity of QueenslandSt LuciaAustralia
  6. 6.The University of the Highlands and IslandsInvernessUK
  7. 7.Sullivan Nicolaides PathologyBrisbaneAustralia

Personalised recommendations